A large study (89) of 12,439 BC patients, found no association between survival and manually quantified CD8+ T cells while Sobral-Leite et al. (92), who analyzed TIL based on IHC and DIA, detected that CD8+ T cells were associated with worse clinical outcome and PIK3CA mutations in ER-positive BC. Here, CD8A is linked to breast cancer.